Evidence map›Paper›PMID 41430398›Full record

ArticleLeukemia2026

Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma.

Martin Grözinger, Muriel Schlanke, Jana Gröne, Stella Erdmann, Marina Hajiyianni, Alexandra M Poos, Heidi Thierjung, Elias K Mai, Sandra Sauer, Dorothee Kaudewitz and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Martin GrözingerGerman Cancer Research Center (DKFZ), Division of Radiology, Heidelberg, Germany.
Muriel SchlankeGerman Cancer Research Center (DKFZ), Division of Radiology, Heidelberg, Germany.
Jana GröneGerman Cancer Research Center (DKFZ), Division of Radiology, Heidelberg, Germany.ORCID 0009-0006-3964-7946
Stella ErdmannInstitute of Medical Biometry, University of Heidelberg, Heidelberg, Germany, Heidelberg, Germany.
Marina HajiyianniHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Alexandra M PoosHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Heidi ThierjungGerman Cancer Research Center (DKFZ), Division of Radiology, Heidelberg, Germany.
Elias K MaiHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-6226-1252
Sandra SauerHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID 0000-0001-5552-3149
Dorothee KaudewitzDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Kaya VeelkenHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Christian S MichelHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID 0009-0004-1596-3763
Jan Hendrik FrenkingHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID 0009-0001-9682-2601
Lilli Sophie SesterHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID 0009-0004-2233-5896
Tim Frederik WeberClinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Heidelberg, Germany.
Sam SedaghatClinic for Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, Heidelberg, Germany.
Markus WennmannGerman Cancer Research Center (DKFZ), Division of Radiology, Heidelberg, Germany.
Carsten Müller-TidowDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-7166-5232
Heinz-Peter SchlemmerGerman Cancer Research Center (DKFZ), Division of Radiology, Heidelberg, Germany.
Stefan DelormeGerman Cancer Research Center (DKFZ), Division of Radiology, Heidelberg, Germany.
Marc S RaabHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID 0000-0003-4181-6922
Hartmut GoldschmidtHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID 0000-0003-0961-0035
Niels WeinholdHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-5464-3234
Lukas JohnHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany. lukas.john@med.uni-heidelberg.de.ORCID 0000-0001-8178-6890

Funding

Celgene (Celgene Corporation) N/A-NI-MM-PI-13884
6 · The paper itself

Abstract

Whole-body imaging plays a critical role in assessing multiple myeloma (MM). The structured scoring systems MY-RADS and KIM score have primarily been developed for newly diagnosed patients (NDMM). However, their application and prognostic significance in relapsed/refractory multiple myeloma (RRMM) remains uncertain. To clarify this, we evaluated whole body magnetic resonance imaging (MRI) data from 46 RRMM patients and compared findings to 68 NDMM patients from the GMMG-HD7 trial using both scoring systems. Despite similar overall disease burden, RRMM patients showed significant differences, characterized by increased paramedullary and extramedullary disease and reduced diffuse marrow infiltration compared to NDMM. Both MY-RADS and KIM scores independently correlated with progression-free and overall survival in RRMM. These results highlight distinct biological patterns in RRMM, emphasizing a shift towards bone marrow-independent growth. Our findings suggest that in RRMM, iliac crest biopsies may underestimate disease burden, underlining the importance of imaging complementing bone marrow diagnostics.

Indexed as

Magnetic Resonance ImagingMultiple MyelomaNeoplasm Recurrence, LocalWhole Body ImagingAdultAgedBone MarrowDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedPrognosis

Identifiers

PMID41430398
PMCPMC12875875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.